Evercore ISI is adding Elevance Health (ELV) to the firm’s “Tactical Outperform” list for Q2, telling investors that the company is poised for “significant upside EPS this year” if current trends hold or improve, helping maintain stock momentum despite the recent move through Q2 earnings. However, the analyst is not upgrading shares as the firm is still worried about the potential for Medicaid to see some headwinds in 2027 from OBBBA work requirements, the analyst added. Evercore has an In Line rating and $360 price target on Elevance shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Omega takes new stakes in Capital One and Amazon, exits Occidental
- Elevance Health Shareholders Back Directors, Pay and Auditor
- Alignment Healthcare names CEO John Kao chairman, Shane Hochradel COO
- MercadoLibre, T-Mobile, Corbus, Celestica, Elevance Trending With Analysts
- Midday Fly By: Seagate reports Q3 beat, Visa reports mixed Q2